Tian Zhang | Scholars@Duke

Tian Zhang
Assistant Professor of Medicine

Current Appointments & Affiliations

Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2017
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2015

Contact Information

DUMC 103861, Durham, NC 27710
Dept of Medicine, Box 103861, Durham, NC 27710
tian.zhang2@duke.edu (919) 668-4667

Background
Education, Training, & Certifications
- M.H.S., Duke University School of Medicine 2019
- Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine 2012 - 2015
- Internal Medicine Residency, Medicine, Duke University School of Medicine 2009 - 2012
- M.D., Harvard Medical School 2009
Duke Appointment History
- Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2015 - 2017
Research
Selected Grants
External Relationships
- ASCO
- AbbVie
- Archimmune Therapeutics
- AstraZeneca
- Bayer
- Bristol-Myers Squibb
- Capio Biosciences
- Dava Oncology
- Exelixis, Inc.
- Foundation medicine
- Genomic Health, Inc.
- Guidepoint Global
- Janssen Pharmaceuticals (Johnson & Johnson)
- MJH Associates
- Merck
- Merrimack Pharmaceuticals, Inc.
- Novartis
- OmniSeq
- Personal Genome Diagnostics
- Pfizer Inc.
- Roche/Genentech
- Sanofi-Aventis
- Seattle Genetics
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Bakthavatsalam, Subha, Petpailin Wiangnak, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.” Bioorg Med Chem Lett 30, no. 11 (June 1, 2020): 127148. https://doi.org/10.1016/j.bmcl.2020.127148.
    Full Text Link to Item
  - Bu, Jiyoon, Ashita Nair, Luke J. Kubiatowicz, Michael J. Poellmann, Woo-Jin Jeong, Marco Reyes-Martinez, Andrew J. Armstrong, et al. “Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.” Biosens Bioelectron 162 (May 1, 2020): 112250. https://doi.org/10.1016/j.bios.2020.112250.
    Full Text Link to Item
  - Brady-Nicholls, Renee, John D. Nagy, Travis A. Gerke, Tian Zhang, Andrew Z. Wang, Jingsong Zhang, Robert A. Gatenby, and Heiko Enderling. “Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation.” Nat Commun 11, no. 1 (April 9, 2020): 1750. https://doi.org/10.1038/s41467-020-15424-4.
    Full Text Link to Item
  - Labriola, Matthew Kyle, Jason Zhu, Rajan Gupta, Shannon McCall, Jennifer Jackson, Eric F. Kong, James R. White, et al. “Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.” J Immunother Cancer 8, no. 1 (March 2020). https://doi.org/10.1136/jitc-2019-000319.
    Full Text Link to Item
  - Bitting, Rhonda L., Patrick Healy, Daniel J. George, Monika Anand, Sung Kim, Tina Mayer, Carol Winters, et al. “Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.” Eur Urol Oncol, February 13, 2020. https://doi.org/10.1016/j.euo.2020.01.005.
    Full Text Link to Item
  - Marshall, Ariela L., Renee K. Dversdal, Martina Murphy, Donna M. Prill, Tian Zhang, and Shikha Jain. “WOMENtorship: The #WomenInMedicine perspective.” Med Teach 42, no. 2 (February 2020): 228–30. https://doi.org/10.1080/0142159X.2019.1671967.
    Full Text Link to Item
  - Zhang, Tian, Lawrence I. Karsh, Michael J. Nissenblatt, and Steven E. Canfield. “Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.” Clin Genitourin Cancer 18, no. 1 (February 2020): 1–10. https://doi.org/10.1016/j.clgc.2019.09.015.
    Full Text Link to Item
  - Mi, Yu, Feifei Yang, Cameron Bloomquist, Youli Xia, Bo Sun, Yanfei Qi, Kyle Wagner, Stephanie A. Montgomery, Tian Zhang, and Andrew Z. Wang. “Biologically Targeted Photo-Crosslinkable Nanopatch to Prevent Postsurgical Peritoneal Adhesion.” Adv Sci (Weinh) 6, no. 19 (October 2, 2019): 1900809. https://doi.org/10.1002/advs.201900809.
    Full Text Link to Item
  - Wang, Hong, Lu Mao, Tian Zhang, Liming Zhang, Yuteng Wu, Wei Guo, Jingzhou Hu, Houyu Ju, and Guoxin Ren. “Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.” J Oral Pathol Med 48, no. 8 (September 2019): 669–76. https://doi.org/10.1111/jop.12883.
    Full Text Link to Item
  - Kao, Chester, Megan McNamara, Chris Alley, Neil Spector, Shekeab Jauhari, Rajan T. Gupta, Tian Zhang, and Jason Zhu. “A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder.” Clin Genitourin Cancer 17, no. 3 (June 2019): e672–77. https://doi.org/10.1016/j.clgc.2019.03.019.
    Full Text Link to Item
  - Labriola, Matthew K., Kristen A. Batich, Jason Zhu, Megan A. McNamara, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.” Clin Genitourin Cancer 17, no. 3 (June 2019): e513–21. https://doi.org/10.1016/j.clgc.2019.01.017.
    Full Text Link to Item
  - Zhang, Tian, Daniel J. George, and Andrew J. Armstrong. “Precision Medicine Approaches When Prostate Cancer Akts Up.” Clin Cancer Res 25, no. 3 (February 1, 2019): 901–3. https://doi.org/10.1158/1078-0432.CCR-18-2491.
    Full Text Link to Item
  - Conroy, Jeffrey M., Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, et al. “Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.” J Immunother Cancer 7, no. 1 (January 24, 2019): 18. https://doi.org/10.1186/s40425-018-0489-5.
    Full Text Link to Item
  - Zhang, Tian, Andrew J. Armstrong, Daniel J. George, and Jiaoti Huang. “The promise of immunotherapy in genitourinary malignancies.” Precis Clin Med 1, no. 3 (December 2018): 97–101. https://doi.org/10.1093/pcmedi/pby018.
    Full Text Link to Item
  - Bakthavatsalam, Subha, Mark L. Sleeper, Azim Dharani, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Leveraging γ-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells.” Angew Chem Int Ed Engl 57, no. 39 (September 24, 2018): 12780–84. https://doi.org/10.1002/anie.201807582.
    Full Text Link to Item
  - Labriola, Matthew, Wen-Chi Foo, Daniel J. George, and Tian Zhang. “Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report.” Clin Genitourin Cancer 16, no. 3 (June 2018): e509–12. https://doi.org/10.1016/j.clgc.2018.02.017.
    Full Text Link to Item
  - Myung, Ja Hye, Michael J. Eblan, Joseph M. Caster, Sin-Jung Park, Michael J. Poellmann, Kyle Wang, Kevin A. Tam, et al. “Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture.” Clin Cancer Res 24, no. 11 (June 1, 2018): 2539–47. https://doi.org/10.1158/1078-0432.CCR-17-3078.
    Full Text Link to Item
  - Humeniuk, Michael S., Rajan T. Gupta, Patrick Healy, Megan McNamara, Sundhar Ramalingam, Michael Harrison, Daniel George, Tian Zhang, Yuan Wu, and Andrew J. Armstrong. “Platinum sensitivity in metastatic prostate cancer: does histology matter?” Prostate Cancer Prostatic Dis 21, no. 1 (April 2018): 92–99. https://doi.org/10.1038/s41391-017-0017-6.
    Full Text Link to Item
  - Austin, R Garland, Tony Jun Huang, Mengxi Wu, Andrew J. Armstrong, and Tian Zhang. “Clinical utility of non-EpCAM based circulating tumor cell assays.” Adv Drug Deliv Rev 125 (February 1, 2018): 132–42. https://doi.org/10.1016/j.addr.2018.01.013.
    Full Text Link to Item
  - Koshkin, Vadim S., Pedro C. Barata, Tian Zhang, Daniel J. George, Michael B. Atkins, William J. Kelly, Nicholas J. Vogelzang, et al. “Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.” J Immunother Cancer 6, no. 1 (January 29, 2018): 9. https://doi.org/10.1186/s40425-018-0319-9.
    Full Text Open Access Copy Link to Item
  - Zhu, Jason, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George, and Tian Zhang. “Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.” J Immunother Cancer 6, no. 1 (January 25, 2018): 4. https://doi.org/10.1186/s40425-018-0314-1.
    Full Text Open Access Copy Link to Item
  - Tian, Xi, Michael E. Werner, Kyle C. Roche, Ariel D. Hanson, Henry P. Foote, Stephanie K. Yu, Samuel B. Warner, et al. “Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds.” Nat Biomed Eng 2 (2018): 443–52.
    Link to Item
  - Zhu, Jason, Matthew Tucker, Endi Wang, Joel S. Grossman, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.” Clin Genitourin Cancer 15, no. 6 (December 2017): e1137–41. https://doi.org/10.1016/j.clgc.2017.07.005.
    Full Text Open Access Copy Link to Item
  - Zhang, Tian, and Andrew J. Armstrong. “The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.” J Clin Oncol 35, no. 28 (October 1, 2017): 3175–77. https://doi.org/10.1200/JCO.2017.74.7931.
    Full Text Link to Item
  - Humeniuk, Michael S., Tian Zhang, and Andrew J. Armstrong. “Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers.” Cancer 123, no. 18 (September 15, 2017): 3441–44. https://doi.org/10.1002/cncr.30806.
    Full Text Link to Item
  - Min, Yuanzeng, Kyle C. Roche, Shaomin Tian, Michael J. Eblan, Karen P. McKinnon, Joseph M. Caster, Shengjie Chai, et al. “Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.” Nat Nanotechnol 12, no. 9 (September 2017): 877–82. https://doi.org/10.1038/nnano.2017.113.
    Full Text Link to Item
  - Ramalingam, Sundhar, Michael S. Humeniuk, Rachel Hu, Julia Rasmussen, Patrick Healy, Yuan Wu, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.” Urol Oncol 35, no. 6 (June 2017): 418–24. https://doi.org/10.1016/j.urolonc.2016.12.016.
    Full Text Link to Item
  - Tian, Jing, Yuangzeng Min, Zachary Rodgers, Xiaomeng Wan, Hui Qiu, Yu Mi, Xi Tian, et al. “Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer.” Nanomedicine 13, no. 3 (April 2017): 1301–7. https://doi.org/10.1016/j.nano.2016.11.007.
    Full Text Link to Item
  - Zhang, Tian, Se Eun Park, Cierra Hong, and Daniel J. George. “Cabozantinib in genitourinary malignancies.” Future Oncol 13, no. 8 (April 2017): 755–65. https://doi.org/10.2217/fon-2016-0358.
    Full Text Link to Item
  - Caster, Joseph M., Artish N. Patel, Tian Zhang, and Andrew Wang. “Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials.” Wiley Interdiscip Rev Nanomed Nanobiotechnol 9, no. 1 (January 2017). https://doi.org/10.1002/wnan.1416.
    Full Text Link to Item
  - Ma, X., Y. Wu, T. Zhang, H. Song, H. Jv, W. Guo, and G. Ren. “Ki67 proliferation index as a histopathological predictive and prognostic parameter of oral mucosal melanoma in patients without distant metastases.” Journal of Cancer 8, no. 18 (January 1, 2017): 3828–37. https://doi.org/10.7150/jca.20935.
    Full Text
  - Ma, X., Y. Wu, T. Zhang, H. Song, H. Jv, W. Guo, and G. Ren. “The clinical significance of c-Kit mutations in metastatic oral mucosal melanoma in China.” Oncotarget 8, no. 47 (January 1, 2017): 82661–73. https://doi.org/10.18632/oncotarget.19746.
    Full Text
  - Zhang, Tian, Jun Gong, Manuel Caitano Maia, and Sumanta K. Pal. “Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma.” Am Soc Clin Oncol Educ Book 37 (2017): 337–42. https://doi.org/10.1200/EDBK_175572.
    Full Text Link to Item
  - Tian, Xi, Samuel B. Warner, Kyle T. Wagner, Joseph M. Caster, Tian Zhang, Patricia Ohana, Alberto A. Gabizon, and Andrew Z. Wang. “Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy.” Int J Radiat Oncol Biol Phys 96, no. 3 (November 1, 2016): 547–55. https://doi.org/10.1016/j.ijrobp.2016.06.2457.
    Full Text Link to Item
  - Zhang, Tian, Jason Zhu, Daniel J. George, and Andrew B. Nixon. “Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.” Urol Oncol 34, no. 11 (November 2016): 510–18. https://doi.org/10.1016/j.urolonc.2016.06.020.
    Full Text Link to Item
  - Shao, Zhiying, Andrew Z. Wang, Daniel J. George, and Tian Zhang. “Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.” Asian J Urol 3, no. 4 (October 2016): 268–77. https://doi.org/10.1016/j.ajur.2016.08.013.
    Full Text Link to Item
  - Ware, Kathryn E., Jason A. Somarelli, Daneen Schaeffer, Jing Li, Tian Zhang, Sally Park, Steven R. Patierno, et al. “Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.” Oncotarget 7, no. 31 (August 2, 2016): 50507–21. https://doi.org/10.18632/oncotarget.10476.
    Full Text Open Access Copy Link to Item
  - Hu, Rachel, Daniel J. George, and Tian Zhang. “What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence.” Ther Adv Urol 8, no. 4 (August 2016): 272–78. https://doi.org/10.1177/1756287216645314.
    Full Text Link to Item
  - Kamal, Arif, Tian Zhang, Steve Power, and P Kelly Marcom. “Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures.” J Natl Compr Canc Netw 14, no. 8 (August 2016): 993–98. https://doi.org/10.6004/jnccn.2016.0106.
    Full Text Link to Item
  - Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Chandra Rao, Gabor Kemeny, John H. Strickler, James L. Abbruzzese, et al. “Development of a Novel c-MET-Based CTC Detection Platform.” Mol Cancer Res 14, no. 6 (June 2016): 539–47. https://doi.org/10.1158/1541-7786.MCR-16-0011.
    Full Text Open Access Copy Link to Item
  - Au, Kin Man, Andrew Satterlee, Yuanzeng Min, Xi Tian, Young Seok Kim, Joseph M. Caster, Longzhen Zhang, Tian Zhang, Leaf Huang, and Andrew Z. Wang. “Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.” Biomaterials 82 (March 2016): 178–93. https://doi.org/10.1016/j.biomaterials.2015.12.018.
    Full Text Link to Item
  - Zhu, Jason, Carter T. Davis, Sandra Silberman, Neil Spector, and Tian Zhang. “A role for the androgen receptor in the treatment of male breast cancer.” Critical Reviews in Oncology/Hematology 98 (February 2016): 358–63. https://doi.org/10.1016/j.critrevonc.2015.11.013.
    Full Text
  - Zhang, Tian, and Andrew J. Armstrong. “Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.” Curr Oncol Rep 18, no. 1 (January 2016): 3. https://doi.org/10.1007/s11912-015-0490-9.
    Full Text Link to Item
  - Zhu, Jason, Tian Zhang, Radhika Shah, Arif H. Kamal, and Michael J. Kelley. “Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians.” J Cancer Educ 30, no. 4 (December 2015): 774–78. https://doi.org/10.1007/s13187-015-0798-z.
    Full Text Link to Item
  - Zhang, Tian, and Andrew J. Armstrong. “Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.” Clin Cancer Res 21, no. 20 (October 15, 2015): 4505–7. https://doi.org/10.1158/1078-0432.CCR-15-1613.
    Full Text Open Access Copy Link to Item
  - Zhang, Tian, Mallika S. Dhawan, Patrick Healy, Daniel J. George, Michael R. Harrison, Jorge Oldan, Bennett Chin, and Andrew J. Armstrong. “Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.” Clin Genitourin Cancer 13, no. 4 (August 2015): 392–99. https://doi.org/10.1016/j.clgc.2015.01.004.
    Full Text Link to Item
  - Zhang, Tian, Elizabeth L. Boswell, Shannon J. McCall, and David S. Hsu. “Mismatch repair gone awry: Management of Lynch syndrome.” Crit Rev Oncol Hematol 93, no. 3 (March 2015): 170–79. https://doi.org/10.1016/j.critrevonc.2014.10.005.
    Full Text Link to Item
  - Zhang, Tian, Jason Zhu, Daniel J. George, and Andrew J. Armstrong. “Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.” Expert Opin Pharmacother 16, no. 4 (March 2015): 473–85. https://doi.org/10.1517/14656566.2015.995090.
    Full Text Link to Item
  - Aggarwal, Rahul, Tian Zhang, Eric J. Small, and Andrew J. Armstrong. “Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.” J Natl Compr Canc Netw 12, no. 5 (May 2014): 719–26. https://doi.org/10.6004/jnccn.2014.0073.
    Full Text Link to Item
  - Boggan, Joel C., Tian Zhang, Chris Derienzo, Karen Frush, and Kathryn Andolsek. “Standardizing and Evaluating Transitions of Care in the Era of Duty Hour Reform: One Institution's Resident-Led Effort.” J Grad Med Educ 5, no. 4 (December 2013): 652–57. https://doi.org/10.4300/JGME-D-12-00287.
    Full Text Open Access Copy Link to Item
  - Zhang, Tian, Shiva K. Das, Diane R. Fels, Katherine S. Hansen, Terence Z. Wong, Mark W. Dewhirst, and Gordana Vlahovic. “PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions.” Ajr Am J Roentgenol 201, no. 5 (November 2013): W698–706. https://doi.org/10.2214/AJR.12.9698.
    Full Text Link to Item
  - Zhang, Tian, and Andrew J. Armstrong. “Clinical phenotypes of castration-resistant prostate cancer.” Clin Adv Hematol Oncol 11, no. 11 (November 2013): 707–18.
    Link to Item
  - Zhang, Tian, Andrew Schneider, Erika P. Hamilton, Krish Patel, Arif H. Kamal, Gary H. Lyman, and Jeffrey M. Peppercorn. “Prevalence and impact of correlative science in breast cancer phase II trials.” Breast Cancer Res Treat 139, no. 3 (June 2013): 845–50. https://doi.org/10.1007/s10549-013-2590-2.
    Full Text Link to Item
  - DeRienzo, Christopher M., Karen Frush, Michael E. Barfield, Priya R. Gopwani, Brian C. Griffith, Xiaoyin Jiang, Ankit I. Mehta, et al. “Handoffs in the era of duty hours reform: a focused review and strategy to address changes in the Accreditation Council for Graduate Medical Education Common Program Requirements.” Acad Med 87, no. 4 (April 2012): 403–10. https://doi.org/10.1097/ACM.0b013e318248e5c2.
    Full Text Link to Item
  - Werner, Michael E., Shrirang Karve, Rohit Sukumar, Natalie D. Cummings, Jonathan A. Copp, Ronald C. Chen, Tian Zhang, and Andrew Z. Wang. “Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis.” Biomaterials 32, no. 33 (November 2011): 8548–54. https://doi.org/10.1016/j.biomaterials.2011.07.067.
    Full Text Link to Item
  - Zhang, Tian, Diane R. Fels, Katherine S. Hansen, Shiva K. Das, Terence Z. Wong, Mark W. Dewhirst, and Gordana Vlahovic. “62CUATSM AND 62CUPTSM PET IS A USEFUL IMAGING TOOL FOR HYPOXIA AND PERFUSION IN LUNG CANCER.” Journal of Thoracic Oncology 6, no. 6 (June 1, 2011): S919–20.
    Link to Item
  - Kamal, A., T. Zhang, A. Schneider, K. Patel, E. P. Hamilton, P. K. Marcom, and J. M. Peppercorn. “Outcomes in phase II trials of metastatic breast cancer: Where is the bar?” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 2590.
    Link to Item
  - Patel, K., A. Kamal, T. Zhang, A. Schneider, E. P. Hamilton, and J. M. Peppercorn. “The role of biologic therapy in phase II breast cancer clinical trials.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): e13048.
    Link to Item
  - Schneider, A., T. Zhang, A. Kamal, K. Patel, E. P. Hamilton, and J. M. Peppercorn. “Pharmaceutical involvement in phase II breast cancer clinical trials.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 6104.
    Link to Item
  - Zhang, T., E. P. Hamilton, A. Schneider, K. Patel, A. Kamal, and J. M. Peppercorn. “Prevalence and impact of correlative science in breast cancer phase II trials.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 1046.
    Link to Item
  - Kinsey, Emily N., Tian Zhang, and Andrew J. Armstrong. “Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.” Cancer J 26, no. 1 (n.d.): 64–75. https://doi.org/10.1097/PPO.0000000000000418.
    Full Text Link to Item
- Book Sections
  - Zhang, T., and A. Z. Wang. “Biochemical failure in prostate cancer.” In Prostate Cancer: A Comprehensive Perspective, 807–11, 2013. https://doi.org/10.1007/978-1-4471-2864-9_67.
    Full Text
- Conference Papers
  - Agarwal, Anika, Jennifer Modliszewski, Lauren Davey, Marco Reyes-Martinez, Daniella Runyambo, David Corcoran, Holly Dressman, et al. “Investigating the role of the gastrointestinal microbiome in response to immune checkpoint inhibitors (ICIs) among patients (pts) with metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Battle, Dena, Wendy Kimryn Rathmell, Eric Jonasch, Pavlos Msaouel, Adam P. Stern, Tian Zhang, Daniel J. George, and Michael D. Staehler. “Patient-reported outcomes on treatment-related side effects in renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Brown, Landon Carter, Kunal Desai, Chester Kao, Emily Noelle Kinsey, Patrick Healy, Julie Kephart, Michael Roger Harrison, et al. “A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Desai, Kunal, Landon Carter Brown, Wei Wei, Kimberly D. Allman, Allison Martin, Laura S. Wood, Shilpa Gupta, et al. “Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Zhang, Tian, Julie Kephart, Elizabeth Bronson, Monika Anand, Christine Daly, Ivan Spasojevic, Hannah Berg, et al. “Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Zhang, Tian, Karla V. Ballman, Atish Dipankar Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Tyler Zemla, et al. “PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Zhang, Tian, Yuan Wu, Anika Agarwal, Mark D. Starr, Marco Reyes-Martinez, Monika Anand, Daniella Runyambo, et al. “Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renalcell carcinoma (mRCC) treated with ipilimumab/nivolumab (I plus N).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Kao, Chester, Eric Powers, Michael B. Datto, Michelle Green, Michael Roger Harrison, Andrew J. Armstrong, Daniel J. George, Jeffrey Melson Clarke, John H. Strickler, and Tian Zhang. “Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
    Link to Item
  - Brown, Landon, Emily Kinsey, Chester Kao, Patrick Healy, Andrew Armstrong, Megan McNamara, Sundhar Ramalingam, Michael Harrision, Daniel George, and Tian Zhang. “A retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with Ipilimumab and Nivolumab.” In Journal for Immunotherapy of Cancer, Vol. 7. BMC, 2019.
    Link to Item
  - Kinsey, Emily, Landon Brown, Chester Kao, Patrick Healy, Michael Harrison, Megan McNamara, Andrew Armstrong, Sundhar Ramalingham, Daniel George, and Tian Zhang. “Combination cabozantinib and nivolumab treatment in patients with refractory metastatic renal cell carcinoma (mRCC).” In Journal for Immunotherapy of Cancer, Vol. 7. BMC, 2019.
    Link to Item
  - Choueiri, Toni K., David I. Quinn, Tian Zhang, Howard Gurney, Gurjyot K. Doshi, Patrick Wayne Cobb, Francis Parnis, et al. “Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study.” In Clinical Trials. American Association for Cancer Research, 2019. https://doi.org/10.1158/1538-7445.am2019-ct162.
    Full Text
  - Labriola, Matthew, Jason Zhu, Rajan Gupta, Shannon McCall, Jennifer Jackson, James R. White, Elizabeth Weingartner, et al. “Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 37:e16079–e16079. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e16079.
    Full Text
  - Labriola, Matthew, Jason Zhu, Sachica Cheris, Xin Liu, Kathryn Perkinson, Zuowei Su, Shannon McCall, et al. “Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).” In Journal of Clinical Oncology, 37:e14259–e14259. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e14259.
    Full Text
  - Mara, Alexandria, Jason Zhu, Yuan Wu, Tom Callis, Shan Yang, Edward D. Esplin, Robert L. Nussbaum, et al. “Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer.” In Journal of Clinical Oncology, 37:5062–5062. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5062.
    Full Text
  - Zhang, Tian, Bridget F. Koontz, Scott T. Tagawa, Himanshu Nagar, Rhonda L. Bitting, Bart Frizzell, Julia Rasmussen, et al. “A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).” In Journal of Clinical Oncology, 37:TPS5097–TPS5097. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.tps5097.
    Full Text
  - Zhang, Tian, Karla V. Ballman, Atish Dipankar Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Tyler Zemla, et al. “PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).” In Journal of Clinical Oncology, 37:TPS4596–TPS4596. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.tps4596.
    Full Text
  - Zhu, Jason, Matthew D. Tucker, Chester Kao, Matthew Labriola, Sachica Cheris, Michael B. Datto, Yuan Wu, et al. “Immune checkpoint inhibitor response in tumors with LRP1B variants.” In Journal of Clinical Oncology, 37:e14291–e14291. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e14291.
    Full Text
  - Zhu, Jason, Sarabjot Pabla, Matthew Labriola, Rajan T. Gupta, Shannon McCall, Daniel J. George, Devin Dressman, et al. “Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 37:2595–2595. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.2595.
    Full Text
  - Glenn, Sean T., Sarabjot Pabla, Jason Zhu, Matthew Labriola, Rajan Gupta, Daniel J. George, Shannon McCall, et al. “Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma.” In Journal of Clinical Oncology, 37:62–62. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.8_suppl.62.
    Full Text
  - Pabla, Sarabjot, Jason Zhu, Matthew Labriola, Rajan Gupta, Daniel J. George, Shannon McCall, Edwin Yau, et al. “Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma.” In Journal of Clinical Oncology, 37:61–61. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.8_suppl.61.
    Full Text
  - Zhu, Jason, Sarabjot Pabla, Matthew Labriola, Rajan T. Gupta, Shannon McCall, Daniel J. George, Devin Dressman, et al. “Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 37:63–63. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.8_suppl.63.
    Full Text
  - Armstrong, Andrew J., Rhonda L. Bitting, Patrick Healy, Daniel J. George, Sung Kim, Tina M. Mayer, Carolyn Winters, et al. “Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.” In Journal of Clinical Oncology, 37:29–29. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.29.
    Full Text
  - Harrison, Michael Roger, Michel Khouri, Andrew J. Armstrong, Tian Zhang, Megan Ann McNamara, Monika Anand, Ellen Bratt, et al. “PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET).” In Journal of Clinical Oncology, 37:281–281. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.281.
    Full Text
  - Labriola, Matthew, Jason Zhu, Rajan Gupta, Shannon McCall, Jennifer Jackson, James R. White, Elizabeth Weingartner, et al. “Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 37:589–589. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.589.
    Full Text
  - Labriola, Matthew, Jason Zhu, Rajan Gupta, Shannon McCall, Jennifer Jackson, James R. White, Elizabeth Weingartner, et al. “Characterization of genomic alterations as biomarkers of immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma (mUC).” In Journal of Clinical Oncology, 37:400–400. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.400.
    Full Text
  - Tucker, Matthew D., Jason Zhu, William R. Berry, Sundhar Ramalingam, Tian Zhang, Michael Roger Harrison, Yuan Wu, Patrick Healy, Daniel J. George, and Andrew J. Armstrong. “Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 37:172–172. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.172.
    Full Text
  - Zhang, Tian, Janet S. Staats, Cliburn Chan, Ajjai Shivaram Alva, Peter H. O’Donnell, Michael Roger Harrison, Kristen A. Batich, Veerendra Munugalavadla, Daniel J. George, and Kent J. Weinhold. “Multidimensional flow characterization of circulating immune cells in cisplatin-resistant metastatic urothelial cancer (mUC) patients (pts) treated with pembrolizumab (P) with or without acalabrutinib (acala).” In Journal of Clinical Oncology, 37:357–357. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.357.
    Full Text
  - Zhu, Jason, Matthew Labriola, Sachica Cheris, Xin Liu, Kathryn Perkinson, Zuowei Su, Shannon McCall, et al. “Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).” In Journal of Clinical Oncology, 37:577–577. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.577.
    Full Text
  - Zhu, Jason, Sarabjot Pabla, Matthew Labriola, Rajan T. Gupta, Shannon McCall, Daniel J. George, Devin Dressman, et al. “Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 37:607–607. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.607.
    Full Text
  - Koontz, B. F., K. E. Hoffman, P. Healy, D. J. George, M. R. Harrison, T. Zhang, W. R. Lee, et al. “Two Year Outcomes of Short-Term Potent Androgen Blockade and Definitive Radiation for Intermediate to High Risk Localized Prostate Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 102:S100–S100. Elsevier BV, 2018. https://doi.org/10.1016/j.ijrobp.2018.06.256.
    Full Text
  - Ware, Kathryn E., Santosh Gupta, Jared Eng, Wen-Chi Foo, Lorin Crawford, Garland Austin, Bhairavy Puviindran, et al. “Abstract B038: Convergent hormone therapy resistance mediated by stress/dormancy-like pathways in prostate cancer.” In Poster Presentations Proffered Abstracts. American Association for Cancer Research, 2018. https://doi.org/10.1158/1538-7445.prca2017-b038.
    Full Text
  - George, Daniel J., Elisabeth I. Heath, A Oliver Sartor, Guru Sonpavde, William R. Berry, Patrick Healy, Carolyn Winters, et al. “Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).” In Journal of Clinical Oncology, Vol. 36. AMER SOC CLINICAL ONCOLOGY, 2018.
    Link to Item
  - Sitlinger, Andrea Phillips, Rishi Sachdev, Peter A. Ubel, Charlene Wong, Thomas William LeBlanc, Tian Zhang, David Anderson, and Yousuf Zafar. “Can oral chemotherapy parity laws reduce patients’ out-of-pocket (OOP) costs?” In Journal of Clinical Oncology, 36:6620–6620. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.6620.
    Full Text
  - Zhang, Tian, Janet S. Staats, Cliburn Chan, Michael Roger Harrison, Peter H. O’Donnell, Kristen A. Batich, Tianling Chen, et al. “Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).” In Journal of Clinical Oncology, 36:4533–4533. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.4533.
    Full Text
  - Zhang, Tian, Rebecca Garland Austin, Sally E. Park, Daniella Runyambo, Rengasamy Boominathan, Chandra Rao, Elizabeth Bronson, et al. “Expression of immune checkpoints (ICs) on circulating tumor cells (CTCs) in men with metastatic prostate cancer (mPC).” In Journal of Clinical Oncology, 36:5059–5059. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5059.
    Full Text
  - Koontz, Bridget F., Karen E. Hoffman, Patrick Healy, Daniel J. George, Michael Roger Harrison, Tian Zhang, W Robert Lee, et al. “Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.” In Journal of Clinical Oncology, 36:11–11. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.11.
    Full Text
  - Zhang, Tian, Rebecca Garland Austin, Sally E. Park, Daniella Runyambo, Rengasamy Boominathan, Chandra Rao, Elizabeth Bronson, et al. “Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer (mPC).” In Journal of Clinical Oncology, 36:191–191. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.191.
    Full Text
  - Choueiri, T. K., T. Powles, T. Zhang, D. I. Quinn, J. E. Gschwend, S. S. Wan, and C. Poehlein. “KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC).” In Annals of Oncology, Vol. 28. OXFORD UNIV PRESS, 2017.
    Link to Item
  - Zhang, T., M. Harrison, P. O’Donnell, A. Alva, N. Hahn, L. J. Appleman, J. Cetnar, et al. “Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC).” In Annals of Oncology, Vol. 28. OXFORD UNIV PRESS, 2017.
    Link to Item
  - Bakthavatsalam, Subha, Tian Zhang, and Katherine Franz. “Targeted prodrugs to manipulate copper biology of prostate cancer.” In Abstracts of Papers of the American Chemical Society, Vol. 254. AMER CHEMICAL SOC, 2017.
    Link to Item
  - Dharani, Azim, Subha Bakthavatsalam, Tian Zhang, and Katherine Franz. “Prostate cancer targeted prodrug based on copper prochelator.” In Abstracts of Papers of the American Chemical Society, Vol. 254. AMER CHEMICAL SOC, 2017.
    Link to Item
  - Ware, Kathryn E., Daneen Schaeffer, Tian Zhang, Mariano A. Garcia-Blanco, and Andrew J. Armstrong. “Abstract 1847: AR-V7 regulation during epithelial plasticity.” In Endocrinology. American Association for Cancer Research, 2015. https://doi.org/10.1158/1538-7445.am2015-1847.
    Full Text
  - Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Mark Carle Connelly, Chandra Rao, Gabor Kemeny, John H. Strickler, et al. “Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies.” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Mark Carle Connelly, Chandra Rao, Gabor Kemeny, Herbert Hurwitz, Mariano A. Garcia-Blanco, and Andrew J. Armstrong. “Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal malignancies.” In Journal of Clinical Oncology, 33:84–84. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.3_suppl.84.
    Full Text
  - Zhang, Tian, Mallika S. Dhawan, Patrick Healy, Daniel J. George, Jorge Oldan, Bennett Chin, and Andrew J. Armstrong. “Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 32:e16031–e16031. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e16031.
    Full Text
  - Zhang, Tian, Steve Power, Paul K. Marcom, and Arif Kamal. “Is advanced imaging in early-stage breast cancer ever warranted? Exploring benchmarks for an ASCO Choosing Wisely quality measure.” In Journal of Clinical Oncology, 32:6503–6503. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.6503.
    Full Text
  - Zhang, Tian, Arif Kamal, and Michael J. Kelley. “Comparison of QOPI measure conformance between oncology fellows and attending physicians.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.31_suppl.162.
    Full Text Link to Item
  - Zhang, Tian, Shiva K. Das, Jeffrey Crawford, Terence Wong, Mark W. Dewhirst, and Gordana Vlahovic. “(62)cuatsm and (62)cuptsm PET is a useful imaging tool for hypoxia and perfusion in lung cancer.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Kamal, A., T. Zhang, A. Schneider, K. Patel, E. P. Hamilton, P. K. Marcom, and J. M. Peppercorn. “Outcomes in phase II trials of metastatic breast cancer: Where is the bar?” In Journal of Clinical Oncology, 29:2590–2590. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.2590.
    Full Text
  - Patel, K., A. Kamal, T. Zhang, A. Schneider, E. P. Hamilton, and J. M. Peppercorn. “The role of biologic therapy in phase II breast cancer clinical trials.” In Journal of Clinical Oncology, 29:e13048–e13048. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.e13048.
    Full Text
  - Schneider, A., T. Zhang, A. Kamal, K. Patel, E. P. Hamilton, and J. M. Peppercorn. “Pharmaceutical involvement in phase II breast cancer clinical trials.” In Journal of Clinical Oncology, 29:6104–6104. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.6104.
    Full Text
  - Zhang, T., E. P. Hamilton, A. Schneider, K. Patel, A. Kamal, and J. M. Peppercorn. “Prevalence and impact of correlative science in breast cancer phase II trials.” In Journal of Clinical Oncology, 29:1046–1046. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.1046.
    Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Selected Grants

External Relationships

Selected Publications

Academic Articles

Book Sections

Conference Papers